| Autor: |
Yi‐Hsin Chan, Hsin‐Fu Lee, Chun‐Li Wang, Shang‐Hung Chang, Chih‐Hsin Yeh, Tze‐Fan Chao, Yung‐Hsin Yeh, Shih‐Ann Chen, Chi‐Tai Kuo |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 21 (2019) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.119.013053 |
| Popis: |
Background The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) evaluated rivaroxaban (20/15 mg/d) versus warfarin in patients with atrial fibrillation. A separate trial, J‐ROCKET AF (Japanese ROCKET AF), compared rivaroxaban (15/10 mg/d) and warfarin in Japanese patients with atrial fibrillation. Data about rivaroxaban following J‐ROCKET AF criteria compared with warfarin and ROCKET AF dosage were limited. Methods and Results This retrospective study used medical data from a multicenter healthcare provider in Taiwan that included 3162 patients taking rivaroxaban. Among 2320 patients with an estimated glomerular filtration rate (eGFR) ≥50 mL/min per 1.73 m2, 384 and 1936 patients followed the ROCKET AF (20 mg/d) and J‐ROCKET AF (15 mg/d) recommendation, respectively. Among 842 patients with an eGFR |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text